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BACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC)
considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination were assessed in a
phase II, open, multicentre, uncontrolled study.
METHODS: Treatment consisted of capecitabine 1250mgm2 (or 950mgm2 for patients with a creatinine clearance of
30–50mlmin1) twice daily on days 1–14 and bevacizumab (7.5mg kg1) on day 1 every 3 weeks.
RESULTS: A total of 59 patients agedX70 years with mCRC were enrolled. In an intention-to-treat analysis, the overall response rate
was 34%, with 71% of patients achieving disease control. Median progression-free survival and overall survival were 10.8 months and
18 months, respectively. In all, 32 patients (54%) had grade 3/4 adverse events (AEs), the most common being hand–foot syndrome
(19%), diarrhoea (9%) and deep venous thrombosis (7%). Four patients died because of treatment-related AEs. A relationship was
detected between creatinine clearance p50mlmin1 and the development of non-bevacizumab-related grade 3/4 AEs. The
incidence of bevacizumab-associated AEs (hypertension, thromboembolic events and proteinuria) was consistent with that of
previous reports in elderly patients.
CONCLUSION: Bevacizumab combined with capecitabine represents a valid therapeutic alternative in elderly patients considered to be
unsuitable for receiving polychemotherapy.
British Journal of Cancer (2010) 102, 1468–1473. doi:10.1038/sj.bjc.6605663 www.bjcancer.com
Published online 27 April 2010
& 2010 Cancer Research UK
Keywords: capecitabine; bevacizumab; colorectal neoplasms; neoplasm metastasis; aged

































































Colorectal cancer (CRC) is the third most frequent tumour in the
world, with one million new cases being diagnosed every year
(Parkin et al, 2005). Its incidence increases considerably with age,
with 18.6 cases per 100 000 inhabitants per year among thoseo65
years of age compared with 307.3 cases per 100 000 inhabitants per
year among those 465 years of age (Ries et al, 2002). In Europe,
the median age of patients diagnosed with CRC is within the
seventh decade of life and 40% of them are older than 74 years
(Gatta et al, 1998). Furthermore, the number of elderly individuals
diagnosed with CRC will probably increase in the upcoming years
if the demographic forecast on population ageing is taken into
account.
Treatment of advanced CRC in the elderly is still a challenge.
Elderly individuals constitute a very heterogeneous population
with regard to their overall health condition, functional
dependence grade, co-morbidities and performance status (PS);
hence, the therapeutic decisions in this population must be
individualised.
Although most authors agree that the fit elderly patient should
receive the same treatment as the youngest (Kohne et al, 2008),
there is more disagreement regarding the best treatment for the
unfit elderly, as conventional treatments may cause higher toxicity
in them. In these cases, some therapeutic guidelines recommend
treatment with monotherapy, such as capecitabine or infusions of
5-fluorouracil (5-FU) modulated with leucovorin (LV), with the
possible addition of bevacizumab (National Comprehensive
Cancer Network (NCCN), 2008). In fact, the subgroup analysis of
a randomised phase II study comparing 5-FU–LV with 5-FU–LV
plus bevacizumab suggested that the effect of bevacizumab was
particularly beneficial in patients with an Eastern Cooperative
Oncology Group (ECOG) PS 40, age 465 years and albumin
p3.5 g 100ml (Fernando and Hurwitz, 2003), characteristics that
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are often observed among the elderly. In addition, in a subsequent
randomised phase II study with 5-FU–LV–bevacizumab combi-
nation vs 5-FU–LV in patients considered unsuitable for
polychemotherapy with irinotecan, a higher overall response rate
(ORR; 26 vs 15.3%, respectively; P¼ 0.055), higher median
progression-free survival (PFS; 9.2 vs 5.5 months, respectively;
P¼ 0.0002) and higher overall survival (OS; 16.6 vs 12.9 months,
respectively; P40.05) were observed for the combination
(Kabbinavar et al, 2005).
Capecitabine (Xeloda; Hoffmann-La Roche, Nutley, NJ, USA)
is an oral fluoropyrimidine that has efficacy similar to that of
5-FU–LV in bolus as first-line treatment of advanced or metastatic
CRC (mCRC; Hoff et al, 2001; Van Cutsem et al, 2001). Results
from a previous study by our group suggested that it was also well
tolerated in patients over 70 years of age with mCRC, in whom
polychemotherapy was not appropriate (Feliu et al, 2005). Even
though the addition of bevacizumab to capecitabine may be an
interesting therapeutic option for these patients, the data
published so far on its efficacy and safety are scarce (Puthillath
et al, 2009).
The purpose of this phase II study was to assess the efficacy and
safety of a bevacizumab–capecitabine combination in the unfit
elderly patient with mCRC.
MATERIALS AND METHODS
Patient eligibility
The main inclusion criteria were: histologically confirmed mCRC,
age X70 years, ECOG PS p2, life expectancy of more than 3
months, X1 measurable lesion according to the Response
Evaluation Criteria in Solid Tumours (RECIST; Therasse et al,
2000) by computed tomography scan and unsuitability for
receiving combination with oxaliplatin or irinotecan chemotherapy
as per clinical judgment (e.g., patients with X2 co-morbidities
according to the Charlson co-morbidity scale (Charlson et al,
1987) or dependence for any of the basic or instrumental activities
of daily living (ADL or IADL); Katz et al, 1963; Lawton, 1988).
Patients who were disease free for at least 6 months after
completion of adjuvant/neoadjuvant chemotherapy were eligible.
Earlier radiotherapy for mCRC was permitted if completed at least
4 weeks before study inclusion and if untreated measurable disease
remained. Patients were required to have adequate haematological,
hepatic and renal function.
The main exclusion criteria were: operable mCRC before
chemotherapy for advanced disease or earlier bevacizumab; CNS
metastasis; clinically significant cardiac disease within the past 12
months; lack of physical integrity of the upper gastrointestinal
tract or malabsorption syndrome; major surgical procedures or
open biopsy, or having experienced significant traumatic injury
within 28 days before study entry; serious non-healing wound,
ulcer or bone fracture; clinical use of full-dose anti-coagulants or
thrombolytics; significant bleeding diathesis or coagulopathy; and
proteinuria X500mg every 24 h.
The study was conducted after approval by the appropriate
independent ethics committee of each site and in accordance with
the Declaration of Helsinki, Good Clinical Practices and local
ethical and legal requirements. All patients provided written
informed consent according to local ethics committee regulations.
Treatment plan
The initial dose of capecitabine was determined according to the
patient’s renal function (creatinine clearance; CrCl). Patients
received a capecitabine dose of 1250mgm2 twice daily
(2500mgm2 total daily dose) if their CrCl 450mlmin1 and
up to 950mgm2 twice daily (1900mgm2 total daily dose) if they
had a CrCl of 30–50mlmin1. Capecitabine was administered for
2 weeks, followed by 1 week of rest. Bevacizumab was administered
as a 30–90min intravenous infusion at a dose of 7.5mg kg1 on
day 1 of a 3-week cycle.
The Cockcroft–Gault formula (Cockcroft and Gault, 1976) was
used to calculate CrCl levels between cycles. If clearance was
o30mlmin1, treatment was stopped. Cycles were repeated every
3 weeks for a minimum of three per patient, unless disease
progression was noted. Patients with a complete response (CR),
partial response or stable disease continued receiving chemo-
therapy until progression or detection of unacceptable adverse
events (AEs).
The administration of bevacizumab was permanently discon-
tinued in case of grade X3 thromboembolic events, grade X3
bleeding or uncontrolled hypertension. In case of grade X3
proteinuria, treatment was withheld until proteinuria improved to
o2 g every 24 h. Dose reductions for grade 2–4 AEs were carried
out for capecitabine as previously described (Van Cutsem et al,
2001).
Study assessments
A screening evaluation was performed at least 3 weeks before
the start of treatment, including a complete anamnesis, physical
examination, a routine blood analysis (haematology and bio-
chemistry), carcinoembryogenic antigen measurement, electro-
cardiogram and imaging studies (chest X-ray; CT of chest,
abdomen or pelvis; abdominal ultrasound or bone scan as needed),
qualitative proteinuria analysis and ECOG PS. The Charlson co-
morbidity scale (Charlson et al, 1987) and the Katz and Lawton
ADL or IADL indices (Katz et al, 1963; Lawton, 1988) were used to
assess patients’ co-morbid burden and general functional status at
baseline. Before each treatment cycle, patients’ ECOG PS, vital
signs, blood biochemistry and qualitative proteinuria analysis were
repeated until final visit.
Tumour response was evaluated radiologically every 9 weeks
(three cycles) or sooner if clinically indicated (together with
carcinoembryogenic antigen measurement) during therapy, and
every 12 weeks during the follow-up period. The same imaging
technique was used throughout the study. RECIST v.1.0 response
guidelines were used (Therasse et al, 2000) to define all responses
after at least 9 weeks of therapy as follows: CR, partial response,
stable disease or progressive disease. Disease control was defined
as the sum of patients achieving a CR, partial response or stable
disease. Confirmation of all responses was required after 4 weeks.
Progression-free survival was defined as the time from the date of
first treatment cycle to the first documentation of progressive
disease or death by any cause. Overall survival was the time
elapsing from the date of the first cycle of treatment until death or
last known follow-up.
Patients were evaluated for AEs during therapy and until 28 days
after the last study drug dose. Adverse events were graded
according to the National Cancer Institute Common Toxicity
Criteria (NCI CTCAE, version 3.0). For hand–foot syndrome, the
previously published grading system was used (Blum et al, 1999).
Statistical methods
The primary objective was to determine the ORR of the
bevacizumab–capecitabine regimen in the intention-to-treat
population. Secondary objectives were to analyse the PFS, OS
and safety profile of the combination.
An optimal two-stage design as described by Simon (1989) was
used. Assuming a minimum efficacy of 15%, we proposed an
achievement of a 30% response rate with the study combination, at
a level of significance of 95% (a error¼ 0.05) and a statistical
power of 80% (b error¼ 0.20). Assuming that 10% of patients
would not be assessable, a total of 59 patients were included.
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As exploratory analyses, a univariate analysis was used to
compare the rate of grade 3/4 AEs according to age (70–79 years vs
X80 years), gender, CrCl (o50 vs X50mlmin1), Charlson
co-morbidity scale (0 vs X1), ECOG PS (0 vs X1) and ADL and
IADL (independent vs dependent). Efficacy rates (response rate,
PFS and OS) according to the Charlson co-morbidity scale were
also compared. Wilcoxon’s signed-rank test (to compare quanti-
tative variables) and Fisher’s exact test (to compare percentages)
were used. The OS and PFS values were calculated using the
Kaplan–Meier method.
RESULTS
Patients’ characteristics
Between August 2006 and January 2008, 59 patients, aged X70
years, with recurrent or mCRC were enrolled in the study. The
patients’ characteristics are shown in Table 1. A total of 22 patients
(37%) had metastasis at diagnosis. Eight patients (13%) had two or
more co-morbidities.
Treatment exposure
A total of 416 treatment cycles with a mean (±s.d.) of 7.1 (±6.5)
cycles per patient were administered. All of the patients enrolled in
the study received at least one dose of the study medication and
were considered evaluable for safety. The mean dose intensity of
capecitabine was 14.6 gm2 per week, this being equivalent to
94.2% of the foreseen dose intensity; it was 7.47mg kg1 per cycle
for bevacizumab, which is equivalent to 99.02% of the scheduled
dose intensity.
Capecitabine dose reduction/discontinuation was required in
35 (59%) patients because of AEs, the most frequent being non-
haematological toxicities, principally, hand–foot syndrome and
diarrhoea. Other causes included laboratory abnormal values,
such as decrease in CrClo30mg 100ml1 and thrombocytopenia/
anaemia. A total of 14 patients (24%) required at least one
bevacizumab dose discontinuation because of AEs, mainly,
hypertension, thromboembolism, proteinuria, haemorrhage and
weight loss, all with a similar incidence rate.
Reasons for discontinuation of treatment were as follows:
disease progression in 25 patients (43%), AEs in 11 (19%) patients,
death for non-tumour causes in 6 patients (10%), patient refusal in
5 (9%), protocol violation in 1 (2%) and other reasons in 10 (17%).
Efficacy
Out of the 59 patients enrolled in the study, 53 were considered to
be evaluable for response. Five patients died and one patient
discontinued study treatment because of AEs before completing
the first 3 months of treatment and before response had been
evaluated. However, they were included in the efficacy analysis as
treatment failures in an intention-to-treat analysis (Table 2).
Overall response rate was 34% (95% confidence interval,
22.4–47.5%), including one patient (2%) with CR and 19 patients
(32%) with partial response. A further 22 patients (37%) achieved
stable disease, giving a disease control rate of 71%. A total of 11
patients (19%) experienced progressive disease.
Progression-free survival median was 10.8 months (95%
confidence interval, 7.6–14.1 months; Figure 1), median OS was
18 months (95% confidence interval, 9.6–26.3 months; Figure 2).
No correlation between response rate, PFS or OS and co-morbidity
at baseline was observed.
A total of 13 patients received second-line chemotherapy after
progression, which consisted of oxaliplatin- (n¼ 7) or irinotecan
(n¼ 6) with or without cetuximab. All these patients had no
co-morbidities (as per Charlson scale) along with an acceptable
IADL and ADL index at baseline, and their tolerability to study
treatment was good.
Table 1 Baseline patient characteristics
Patient characteristics Median (range) n (%)
Age (years) 75 (73–79)
Range
70–74 27 (46)
75–79 19 (32)
X80 13 (22)
Gender
Male 34 (58)
Female 25 (42)
Previous adjuvant treatment
Chemotherapy 7 (12)
Chemotherapy and Radiotherapy 4 (7)
Radiotherapy 1 (2)
ECOG PS
0 26 (44)
1 31 (53)
2 2 (3)
Primary tumour location
Colon 37 (63)
Rectum 15 (25)
Rectum and Colon 7 (12)
No. of metastatic sites
1 32 (54)
2 22 (37)
X3 5 (9)
Localization of the metastasesa
Liver 50 (85)
Lung 27 (46)
Others 14 (24)
Compromised ADL (moderate to total dependence)
Lawton scale (IADL) 19 (32)
Barthel scale (ADL) 8 (14)
Co-morbidities
Hypertension 36 (61)
Venous thrombosis 3 (5)
Cardiac disease 3 (5)
Acute cerebrovascular accident history 2 (3)
Charlson co-morbidity scale
0 22 (37)
1 29 (50)
2 6 (10)
X3 2 (3)
Abbreviations: ECOG PS¼ Eastern Cooperative Oncology Group performance
status; ADL¼ activities of daily living; IADL¼ instrumental activities of daily living.
aEach patient may have more than one location.
Table 2 Best response to treatment
Response No. of patients %
Complete response 1 2
Partial response 19 32
Stable disease 22 37
Progressive disease 11 19
Not evaluablea 6 10
aPatients included as treatment failures in the intention-to-treat analysis.
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Safety
Out of 59 patients, 57 (97%) reported at least one treatment-related
emergent AE. The majority (74%) of treatment-related AEs were
considered to be of grade 1/2. Hand–foot syndrome, diarrhoea,
asthenia, pain, mucositis and arterial hypertension were the most
frequent (420%) treatment-related AEs reported (Table 3). In all,
32 patients (54%) experienced grade 3/4 AEs, the most common
being hand–foot syndrome (19%) and diarrhoea (9%). A total of
12 (20%) patients experienced treatment-related arterial hyperten-
sion, this being grade 3 in one patient (2%). Furthermore, four
(7%) patients had grade 3 treatment-related deep venous
thrombosis and two (3%) patients had grade 1 epistaxis. No
arterial thrombotic events (acute myocardial infarction, acute
cerebrovascular accident or peripheral arterial thrombosis) were
reported. Nine patients (15%) died within the first 60 days of the
study: four (7%) were due to progressive disease and five died as a
result of toxicity, which was considered treatment related in four
(mucositis, digestive haemorrhage, haematologic toxicity and
sepsis).
No correlation between the development of grade 3/4 AEs and
age, ECOG, co-morbidity, IADL and ADL at baseline was observed.
A higher frequency of bevacizumab-non-related (excluding
hypertension, bleeding, proteinuria and arterial or venous
thrombotic phenomena) grade 3/4 AEs was noted in those
cycles in which CrCl was p50mlmin1 (23 vs 13%; Po0.05).
Furthermore, the CrCl mean value was significantly lower in cycles
in which a grade 3/4 AE was reported than in cycles not reporting
this AE grade (55 vs 62mlmin1, respectively; Po0.05).
DISCUSSION
This is the first complete phase II study that analyses the efficacy
and tolerability of bevacizumab combined with capecitabine
chemotherapy in the elderly with mCRC. The efficacy of this
regimen was noteworthy, with a 34% ORR, a disease control
achievement in 71% of the patients and a median PFS and median
OS of 10.8 and 18 months, respectively. These results seem to be
better than those reported with the 5-FU–LV–bevacizumab
regimen (ORR 26%, median PFS: 9.2 months and median OS:
16.6 months; Kabbinavar et al, 2005). Furthermore, they sub-
stantiate the results of a recent underpowered study by Puthillath
et al, (2009) in 16 elderly subjects with mCRC treated with
biweekly bevacizumab–capecitabine, in which a 25% ORR, a
median PFS of 9.5 months and a median OS of 21 months were
achieved. It should be noted that a 24% ORR and a median PFS of
7 months were achieved in a previous study conducted by our
group in elderly subjects treated with capecitabine monotherapy
(Feliu et al, 2005). Thus, bearing in mind the need for caution
when results from different studies are compared, the current
results support the beneficial effect of adding bevacizumab to first-
line chemotherapy or capecitabine monotherapy for mCRC.
These results should be considered within the context of the
elderly population studied and should be extrapolated with caution
to the unfit geriatric population not included in clinical trials. In
our study, a specific criterion to be eligible was the unsuitability to
receive polychemotherapy because of the greater susceptibility of
this patient population to treatment-related AEs. In fact, our
patients often had some form of associated co-morbidity or a
suboptimal IADL or ADL score. Nevertheless, there were also a
number of patients not fulfilling any of these characteristics
included, as they were not considered to be optimal for
polychemotherapy merely on the basis of physician’s subjective
criteria. Furthermore, although unsuitability for receiving combi-
nation chemotherapy was an inclusion criterion, a few patients
received these agents as second-line treatment according to
clinician judgment in view of their good co-morbidity status at
baseline and their good tolerability to the study drugs. Similar to
other authors (Kabbinavar et al, 2005), we consider that these
patients, despite their unfavourable characteristics, may benefit
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Table 3 Most common (X5%) treatment-related AEs per patient
Grade 1/2 Grade 3/4
NCI-CTCAE toxicity n (%) n (%)
Hand-foot syndrome 16 (27) 11 (19)
Diarrhoea 21 (36) 5 (9)
Asthenia 18 (31) 2 (3)
Pain 10 (17) 3 (5)
Mucositis 11 (19) 2 (3)
Arterial hypertension 11 (19) 1 (2)
Thrombocytopenia 5 (9) 2 (3)
Anorexia 6 (10) 1 (2)
Vomiting 6 (10) —
Nausea 6 (10) —
Anaemia 4 (7) 1 (2)
Deep venous thrombosis — 4 (7)
Neutropenia 1 (2) 2 (3)
Abdominal pain 3 (5) —
Infection 3 (5) —
Abbreviations: AE¼ adverse event; NCI-CTCAE¼National Cancer institute Com-
mon Toxicity Criteria.
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from less-aggressive therapeutic alternatives. In this respect, a
recent phase III randomised study (Tebbutt et al, 2009) in
relatively elderly patients with unresecable mCRC previously
untreated also found that the addition of bevacizumab to
capecitabine significantly improved PFS without either significant
toxicity or impairment in their quality of life.
Overall, the toxicity observed with the bevacizumab–capecita-
bine combination in the current study was acceptable, with hand–
foot syndrome and diarrhoea being the most commonly reported
related AEs. Although up to 54% of the patients reported grade 3/4
AEs, this percentage was much lower than the 87% reported with
the 5-FU–LV–bevacizumab regimen in a population of patients
with similar characteristics (Kabbinavar et al, 2005). This is
probably due to the lower rate of grade 3/4 diarrhoea observed in
our study (9%) compared with that reported by (39%). Hand–food
syndrome, which may be of special importance in this patient
population as it may contribute to falls in the elderly, was reported
by 46% patients in our study, and was rated grade 3/4 in 19% of
patients. The frequency of these AEs was similar to that reported in
another study with the same bevacizumab–capecitabine regimen
in patients with advanced breast cancer (Miller et al, 2005). With
regard to bevacizumab-associated AEs, even though 61% of
patients had been previously diagnosed with hypertension, only
one (3%) reported treatment-related grade 3 hypertension. No
grade 4 hypertension was reported. The proportion of patients who
developed grade 3 deep venous thrombosis (7%) did not differ
from that reported in other studies (Kabbinavar et al, 2005; Miller
et al, 2005). Although age X65 years and a history of arterio-
sclerosis are risk factors for arterial thromboembolic events during
treatment with bevacizumab (Scappaticci et al, 2007), this type of
event was not reported in our study. Thus, age alone should not
preclude patients with mCRC from receiving bevacizumab-contain-
ing therapy, and the risk–benefit balance must be weighted carefully
for each patient individually. In fact, in a retrospective analysis of
pooled cohorts of older patients from two studies on bevacizumab in
mCRC, the risks for bevacizumab-associated events did not seem to
be greater than those seen in younger patients (Kabbinavar et al,
2009). Moreover, the benefit derived by older patients with mCRC on
adding bevacizumab to first-line chemotherapy was similar to that of
younger patients without substantial increase in toxicity, according to
the results of the bevacizumab Expanded Access Trial (BEAT; Van
Cutsem et al, 2009).
A relationship was found between renal function before the
administration of each chemotherapy cycle and subsequent
reporting of grade 3/4 AEs. Thus, caution should be exercised
in this group of vulnerable elderly subjects regarding their
renal function, and CrCl should be calculated before each
chemotherapy cycle. Furthermore, administration of capecitabine
in elderly patients with CrCl p50mlmin1 should be considered
on an individualised basis, as there is a greater risk of AEs
(23% grade 3/4 AEs), even though the dose is reduced according
to the common recommendations. In addition, clear instructions
must be provided both to the patient and to his/her caregiver
on the management of acute AEs, such as diarrhoea, mucositis
or fever through regular telephone contact with their doctor
or nurse.
Recently, results of some randomised studies in mCRC point to
a similar survival rate irrespective of whether a first-line
polychemotherapy is used in the first instance and treatment is
changed to monotherapy after progression, or monotherapy
(e.g., 5-FU or capecitabine) is used in the first instance, followed
by polychemotherapy on progression (Koopman et al, 2007;
Seymour et al, 2007a, b). In reality, no significant differences
between the different chemotherapy regimens (5-FU plus oxali-
platin, capecitabine plus oxaliplatin, 5-FU–LV monotherapy or
capecitabine monotherapy) were detected in PFS or in OS in a
recent study (FOCUS 2) conducted in 466 elderly or frail patients
with mCRC, despite the greater response rate observed with
polychemotherapy than with monotherapy (42 vs 39% vs 15 vs
15%, respectively; Seymour et al, 2007a, b). Thus, when palliative
treatment is the objective, it is reasonable to begin with
monotherapy and then to consider a second line of polychemo-
therapy after progression. In that respect, the bevacizumab–
capecitabine combination might be an interesting option in
selected patients.
In conclusion, our results suggest that elderly patients with some
vulnerability criterion (prefrail) unsuitable for receiving first-line
polychemotherapy may benefit from bevacizumab in combination
with capecitabine with an acceptable toxicity profile. Nevertheless,
the most suitable therapeutic regimen for this group of patients is
still pending and future studies particularly designed for this
elderly population are needed.
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